Related Experiment Videos
Current safety issues with quadrivalent meningococcal conjugate vaccines
Tanya R Myers1,2, Michael M McNeil1
1a Immunization Safety Office, Division of Healthcare Quality Promotion , National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Human Vaccines & Immunotherapeutics
|September 22, 2017
Summary
Quadrivalent meningococcal conjugate vaccines are crucial for preventing invasive meningococcal disease. Safety reviews show minimal risks, like Guillain-Barré syndrome and Bell
Area of Science:
- Vaccinology
- Infectious Disease Epidemiology
- Public Health
Background:
- Invasive meningococcal disease (IMD) is a rare but severe illness.
- Quadrivalent meningococcal conjugate vaccines (MenACWY) are key for IMD prevention in adolescents.
- Two MenACWY vaccines, Menactra and Menveo, are available in the US.
Purpose of the Study:
- To review the current safety profile of MenACWY vaccines.
- To identify areas for future safety research on MenACWY vaccines.
Main Methods:
- Review of existing safety data and published literature.
- Analysis of reported adverse events following MenACWY vaccination.
- Assessment of potential vaccine-associated risks.
Main Results:
- Early concerns regarding Menactra and Guillain-Barré syndrome (GBS) indicated a very low potential risk (≤0.66/million).
- Recent studies suggest an elevated risk of Bell's palsy with Menveo only when co-administered with other vaccines.
- No association between Menveo and Bell's palsy was found when administered alone.
Conclusions:
- MenACWY vaccines have a generally favorable safety profile.
- Continued safety surveillance and research are important for understanding rare adverse events.
- Further research should focus on clarifying specific risk factors and vaccine-specific safety profiles.